CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CS-2023 to treat meningitis; CS-2028 for treating multivalent conjugate vaccine; CS-2032 for hingles; CS-2036 to treat polio; CS-2047 for treating tetanus; and CS-2201 DTcP for combination vaccine. The company was incorporated in 2009 and is headquartered in Tianjin, the People’s Republic of China.
Metrics to compare | 688185 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship688185PeersSector | |
---|---|---|---|---|
P/E Ratio | −74.6x | −16.5x | −0.5x | |
PEG Ratio | −0.82 | 0.29 | 0.00 | |
Price/Book | 3.4x | 6.5x | 2.6x | |
Price / LTM Sales | 18.9x | 23.5x | 3.3x | |
Upside (Analyst Target) | −14.0% | 0.6% | 43.5% | |
Fair Value Upside | Unlock | −8.2% | 6.9% | Unlock |